MedPath

扬子江药业集团江苏海慈生物药业有限公司

Ownership
-
Established
2005-02-22
Employees
-
Market Cap
-
Website
https://haici.yangzijiang.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

69

NMPA:69

Drug Approvals

Dyclonine Hydrochloride

Product Name
盐酸达克罗宁
Approval Number
国药准字H20073452
Approval Date
Feb 11, 2022
NMPA

Milrinone

Product Name
米力农
Approval Number
国药准字H20123132
Approval Date
Nov 8, 2021
NMPA

Ropivacaine Mesylate

Product Name
甲磺酸罗哌卡因
Approval Number
国药准字H20070066
Approval Date
May 26, 2021
NMPA

Venlafaxine Hydrochloride

Product Name
盐酸文拉法辛
Approval Number
国药准字H20067157
Approval Date
Oct 21, 2020
NMPA

Somatostatin

Product Name
生长抑素
Approval Number
国药准字H20066707
Approval Date
Oct 21, 2020
NMPA

Carboplatin

Product Name
卡铂
Approval Number
国药准字H20065621
Approval Date
Oct 21, 2020
NMPA

Vecuronim Bromide

Product Name
维库溴铵
Approval Number
国药准字H20066940
Approval Date
Oct 21, 2020
NMPA

Cetirizine Hydrochloride

Product Name
盐酸西替利嗪
Approval Number
国药准字H19980060
Approval Date
May 12, 2020
NMPA

Erdosteine

Product Name
厄多司坦
Approval Number
国药准字H20030839
Approval Date
May 11, 2020
NMPA

Alendronate Sodium

Product Name
阿仑膦酸钠
Approval Number
国药准字H20057738
Approval Date
May 11, 2020
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.